Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue

Vrouenraets, S M E; Wit, F W N M; Garcia, E Fernandez; Huber, M; Brinkman, K; Moyle, G; Domingo, P; Tarr, P E; Podzamczer, D; Ristola, M; Gatell, J M; Livrozet, J M; Furrer, H; Reiss, P; PREPARE Study Group, (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV clinical trials, 13(2), pp. 103-10. St. Louis, Mo.: Thomas Land Publishers

Full text not available from this repository. (Request a copy)

Whether zidovudine (AZT)-associated lipoatrophy occurrence differs by concomitant exposure to protease (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) remains unclear. Baseline body composition data from a randomized trial in subjects stable on first-line AZT-based therapy were used to explore this issue.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

ISSN:

1528-4336

Publisher:

Thomas Land Publishers

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:37

Last Modified:

17 Mar 2015 21:28

PubMed ID:

22510357

Web of Science ID:

000301894100005

URI:

https://boris.unibe.ch/id/eprint/14865 (FactScience: 222001)

Actions (login required)

Edit item Edit item
Provide Feedback